Rebus Biosystems is a venture-backed Silicon Valley-based life science technology company creating revolutionary tools to enable spatial omics research without compromise.
Our first instrument, the Rebus Esper™, is a fully integrated, automated spatial omics platform that delivers quantitative single-molecule, single–cell data with subcellular resolution. Advanced imaging, on-system chemistry, and intuitive software are brought together into a single system, providing a streamlined, end-to-end solution requiring minimal hands-on time. The Rebus Esper enables analysis of cells in their native tissue contexts at high throughput. Biological molecules can be analyzed directly in and across large tissue sections.
The Rebus Esper is a single-instrument solution designed to deliver high-throughput spatial data from a multitude of assays provided as all–inclusive kits by Rebus Biosystems. The first assay to be released on the Rebus Esper is the Esper™ High Fidelity assay, which enables multiplex analysis of gene expression with exquisite sensitivity and specificity. Forthcoming assays will address a wide range of experimental needs and analytes, while always taking advantage of the resolution, scale and speed of the Rebus Esper.
Illuminating the Spectrum of Spatial Discovery
Tom Willis, Ph.D.
Interim Chief Executive Officer
Josh Ryu, PhD
Chief Technology Officer and Co-Founder
Chief Commercial Officer
Chief Financial Officer
Gloria Chui, PhD
Principal Scientist, Reagent Products
Simone Codeluppi, PhD
Principal Scientist, Bioinformatics
Hojin Lee, MS
VP Human Resources
The following products are covered by at least one or more of the following U.S. patents. This page serves as notice under 35 U.S.C. § 287(a) for the following products.
8,502,867; 10,429,665; 16/262,429; 13/999,508;
9,458,501; 9,465,228; 16/567,710; 9,772,505